Ab­b­Vie toss­es its triplet ther­a­py for cys­tic fi­bro­sis, leav­ing Ver­tex to reign supreme

Ab­b­Vie went all in on cys­tic fi­bro­sis a few years ago, shelling out $245 mil­lion for a port­fo­lio of drugs from Gala­pa­gos in the hopes of de­thron­ing Ver­tex’s block­buster Trikaf­ta. On Fri­day, it be­came clear that Ver­tex still reigns supreme — at least for now.

Ab­b­Vie’s send­ing its ex­per­i­men­tal triplet ther­a­py to the scrap heap af­ter it whiffed on an in­ter­im analy­sis in a Phase II proof-of-con­cept study, ex­ecs re­vealed dur­ing the Q1 call.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER